Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Road, Room 5002-B, Boston, MA, 02115, USA.
Ribon Therapeutics, 35 Cambridgepark Drive Suite 300, Cambridge, MA, 02140, USA.
Curr Allergy Asthma Rep. 2023 Jan;23(1):1-11. doi: 10.1007/s11882-022-01052-z. Epub 2022 Nov 29.
The purpose of this literature review was to review the latest advancements with biologics in rapid drug desensitization. Our methodology was to highlight both desensitization to biologics themselves and the use of biologics in desensitization to both biologic and nonbiologic drugs.
Biologics are a vast category of drugs that include monoclonal antibodies, nanobodies, modern vaccinations, and even hormones. Desensitization to biologics can be safely performed through standardized procedure. Biomarkers are used both in vitro and in vivo to help identify and classify hypersensitivity reactions. Hypersensitivity reactions to the mRNA vaccinations against SARS-CoV-2 present their own unique challenges to management. There are specific excipients in monoclonal antibodies that are thought to be responsible for many of their hypersensitivity reactions. Certain biologics can even be used to assist in desensitization to other drugs. Rapid drug desensitization is a standardized procedure that may be able to help many patients who have experienced hypersensitivity reactions to biologics and would best be treated with them to continue to receive them. Biologic drugs have opened a new era in medicine for the prevention and treatment of infectious diseases, cancer, and inflammatory diseases. Hypersensitivity reactions to biologics are quite common. This literature review presents the latest advancements in our understanding of hypersensitivity reactions to biologics, how rapid drug desensitization can be used to continue therapy despite history of hypersensitivity, and how biologics themselves can be used to aid in desensitization itself.
本文旨在综述生物制剂在快速药物脱敏中的最新进展。我们的方法是强调生物制剂本身的脱敏以及生物制剂在生物制剂和非生物制剂脱敏中的应用。
生物制剂是一大类药物，包括单克隆抗体、纳米抗体、现代疫苗，甚至还有激素。通过标准化程序可以安全地对生物制剂进行脱敏。生物标志物被用于体外和体内，以帮助识别和分类过敏反应。针对 SARS-CoV-2 的 mRNA 疫苗的过敏反应提出了其自身独特的管理挑战。单克隆抗体中的某些赋形剂被认为是许多过敏反应的原因。某些生物制剂甚至可以用于协助其他药物的脱敏。快速药物脱敏是一种标准化程序，它可以帮助许多经历过生物制剂过敏反应并最好使用它们治疗的患者继续接受治疗。生物药物为传染病、癌症和炎症性疾病的预防和治疗开辟了一个新时代。生物制剂过敏反应很常见。本文综述介绍了我们对生物制剂过敏反应的最新理解，以及如何在有过敏反应史的情况下使用快速药物脱敏继续治疗，以及生物制剂本身如何用于协助脱敏本身。
